Zhejiang Jingxin Pharmaceutical Co Ltd Capital Reinvestment Ratio
Zhejiang Jingxin Pharmaceutical Co Ltd capital reinvestment ratio. Zhejiang Jingxin Pharmaceutical Co Ltd (002020) has a Capital Reinvestment Ratio of 0.16x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥227.64 Million) in capital expenditures (CN¥35.55 Million). Check 002020 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Zhejiang Jingxin Pharmaceutical Co Ltd (2002–2025)
Capital reinvestment ratio of Zhejiang Jingxin Pharmaceutical Co Ltd from 2002 to 2025. This chart tracks Zhejiang Jingxin Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 22 annual periods. Also explore net asset growth rate of Zhejiang Jingxin Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Zhejiang Jingxin Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (2002–2025)
Zhejiang Jingxin Pharmaceutical Co Ltd capital reinvestment ratio by year from 2002 to 2025. For the full cash flow conversion analysis, see 002020 cash flow metrics.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.26x | CN¥781.35 Million | CN¥202.85 Million | ▼ -24.8% |
| 2024 | 0.35x | CN¥726.16 Million | CN¥250.65 Million | ▼ -45.2% |
| 2023 | 0.63x | CN¥824.69 Million | CN¥519.51 Million | ▲ +4.6% |
| 2022 | 0.60x | CN¥855.78 Million | CN¥515.57 Million | ▼ -45.6% |
| 2021 | 1.11x | CN¥365.02 Million | CN¥404.43 Million | ▲ +70.2% |
| 2020 | 0.65x | CN¥513.21 Million | CN¥334.00 Million | ▲ +3.3% |
| 2019 | 0.63x | CN¥535.30 Million | CN¥337.33 Million | ▲ +36.2% |
| 2018 | 0.46x | CN¥523.40 Million | CN¥242.19 Million | ▲ +58.8% |
| 2017 | 0.29x | CN¥385.01 Million | CN¥112.19 Million | ▼ -22.7% |
| 2016 | 0.38x | CN¥252.69 Million | CN¥95.26 Million | ▼ -52.3% |
| 2015 | 0.79x | CN¥144.69 Million | CN¥114.31 Million | ▲ +75.5% |
| 2014 | 0.45x | CN¥210.49 Million | CN¥94.75 Million | ▼ -53.8% |
| 2013 | 0.98x | CN¥111.03 Million | CN¥108.28 Million | ▼ -29.6% |
| 2012 | 1.39x | CN¥60.28 Million | CN¥83.51 Million | ▲ +33.8% |
| 2011 | 1.04x | CN¥69.41 Million | CN¥71.86 Million | ▼ -60.4% |
| 2010 | 2.62x | CN¥59.55 Million | CN¥155.87 Million | ▲ +1655.7% |
| 2009 | 0.15x | CN¥135.38 Million | CN¥20.18 Million | ▼ -89.8% |
| 2008 | 1.46x | CN¥29.98 Million | CN¥43.81 Million | ▼ -32.9% |
| 2005 | 2.18x | CN¥61.82 Million | CN¥134.67 Million | ▼ -85.7% |
| 2004 | 15.26x | CN¥6.43 Million | CN¥98.11 Million | ▲ +889.6% |
| 2003 | 1.54x | CN¥46.18 Million | CN¥71.19 Million | ▲ +46.8% |
| 2002 | 1.05x | CN¥45.50 Million | CN¥47.79 Million | — |